Gossamer Bio (GOSS) EBIAT (2022 - 2025)
Gossamer Bio's EBIAT history spans 4 years, with the latest figure at -$47.2 million for Q4 2025.
- For Q4 2025, EBIAT fell 43.02% year-over-year to -$47.2 million; the TTM value through Dec 2025 reached -$170.4 million, down 201.39%, while the annual FY2025 figure was -$170.4 million, 201.39% down from the prior year.
- EBIAT reached -$47.2 million in Q4 2025 per GOSS's latest filing, up from -$48.2 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $49.2 million in Q2 2024 to a low of -$59.4 million in Q3 2022.
- Average EBIAT over 4 years is -$39.8 million, with a median of -$44.9 million recorded in 2023.
- Peak YoY movement for EBIAT: soared 215.85% in 2024, then crashed 177.74% in 2025.
- A 4-year view of EBIAT shows it stood at -$55.8 million in 2022, then grew by 13.66% to -$48.1 million in 2023, then surged by 31.4% to -$33.0 million in 2024, then crashed by 43.02% to -$47.2 million in 2025.
- Per Business Quant, the three most recent readings for GOSS's EBIAT are -$47.2 million (Q4 2025), -$48.2 million (Q3 2025), and -$38.3 million (Q2 2025).